A sensitive and specific diagnostic panel to distinguish diffuse astrocytoma from astrocytosis: Chromosome 7 gain with mutant isocitrate dehydrogenase 1 and p53

Journal of Neuropathology and Experimental Neurology

Volumn 70, Issue 2, 2011, Pages 110-115

  Camelo Piragua, Sandra ^a   Jansen, Michael ^a   Ganguly, Aniruddha ^a   Kim, James Chulmin ^a   Cosper, Arjola K ^a   Dias Santagata, Dora ^a   Nutt, Catherine L ^a   Iafrate, A John ^a   Louis, David N ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Astrocytoma; Astrocytosis; Chromosome 7; FISH; IDH1; Immunohistochemistry; p53

Indexed keywords

ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE ISOENZYME; OXIDOREDUCTASE; PROTEIN P53; UNCLASSIFIED DRUG;

ARTICLE; ASTROCYTOMA; ASTROCYTOSIS; BRAIN SURGERY; CANCER DIAGNOSIS; CHROMOSOME 7; CLINICAL ARTICLE; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; GENETIC GAIN; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MUTANT; PATHOLOGIST; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; WORLD HEALTH ORGANIZATION;

ASTROCYTOMA; BRAIN NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 7; DIAGNOSIS, DIFFERENTIAL; GENE DOSAGE; GENOTYPE; GLIOSIS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; ISOCITRATE DEHYDROGENASE; ISOENZYMES; MUTATION; TISSUE EMBEDDING; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79251601011     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/NEN.0b013e31820565f9     Document Type: Article

References (25)

1. Colodner KJ, Montana RA, Anthony DC, et al. Proliferative potential of human astrocytes. J Neuropathol Exp Neurol 2005;64:163-69
2. Burger PC, Shibata T, Kleihues P. The use of the monoclonal antibody Ki-67 in the identification of proliferating cells: Application to surgical neuropathology. Am J Surg Pathol 1986;10:611-17
3. Deckert M, Reifenberger G, Wechsler W. Determination of the pro-liferative potential of human brain tumors using the monoclonal antibody Ki-67. J Cancer Res Clin Oncol 1989;115:179-88
4. Louis DN. The p53 gene and protein in human brain tumors. J Neuropathol Exp Neurol 1994;53:11-21
5. Okamoto Y, Di Patre PL, Burkhard C, et al. Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol 2004;108: 49-56
6. Rubio MP, von Deimling A, Yandell DW, et al. Accumulation of wild type p53 protein in human astrocytomas. Cancer Res 1993;53:3465-67
7. Ariza A, von Uexkull-Guldeband C, Mate JL, et al. Accumulation of wild-type p53 protein in progressive multifocal leukoencephalopathy: A flow of cytometry and DNA sequencing study. J Neuropathol Exp Neurol 1996;55:144-49
8. Yaziji H, Massarani-Wafai R, Gujrati M, et al. Role of p53 immunohis-tochemistry in differentiating reactive gliosis from malignant astrocytic lesions. Am J Surg Pathol 1996;20:1086-90
9. Schrock E, Blume C, Meffert MC, et al. Recurrent gain of chromosome arm 7q in low-grade astrocytic tumors studied by comparative genomic hybridization. Genes Chromosomes Cancer 1996;15:199-205
10. Arslantas A, Artan S, Oner U, et al. Genomic alterations in low-grade, anaplastic astrocytomas and glioblastomas. Pathol Oncol Res 2007;13: 39-46
11. Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: A study of 1,010 diffuse gliomas. Acta Neuropathol 2009;118:469-74
12. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009;360:765-73
13. Okada Y, Ohno C, Ueki K, et al. Comparison of numerical change of epidermal growth factor receptor gene among pre- and postradiation glioma, and gliosis, and its clinical use. Brain Tumor Pathol 2007;24: 15-18
14. Camelopiragua S, Jansen M, Ganguly A, et al. Mutant IDH1-specific immunohistochemistry distinguishes diffuse astrocytoma from astrocy-tosis. Acta Neuropathol 2010;119:509-11
15. Horbinski C, Kofler J, Kelly LM, et al. Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffin-embedded glioma tissues. J Neuropathol Exp Neurol 2009;68:1319-25
16. Mott RT, Turner KC, Bigner DD, et al. Utility of EGFR and PTEN numerical aberrations in the evaluation of diffusely infiltrating astrocy-tomas. Laboratory investigation. J Neurosurg 2008;108:330-35
17. Wessels PH, Twijnstra A, Kessels AG, et al. Gain of chromosome 7, as detected by in situ hybridization, strongly correlates with shorter survival in astrocytoma grade 2. Genes Chromosomes Cancer 2002;33:279-84
18. Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol 2009;11:341-47
19. Watanabe T, Nobusawa S, Kleihues P, et al. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 2009;174:1149-53
20. Capper D, Zentgraf H, Balss J, et al. Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol 2009;118:599-601
21. Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009;361: 1058-66
22. Gaal J, Burnichon N, Korpershoek E, et al. Isocitrate dehydrogenase mutations are rare in pheochromocytomas and paragangliomas. J Clin Endocrinol Metab 2010;95:1274-78
23. Kang MR, Kim MS, Oh JE, et al. Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. Int J Cancer 2009;125: 353-55
24. Dias-Santagata D, Akhavanfard S, David SS, et al. Rapid targeted mu-tational analysis of human tumours: A clinical platform to guide personalized cancer medicine. EMBO Mol Med 2010;2:146-58
25. Fuller CE, Perry A. Fluorescence in situ hybridization (FISH) in diagnostic and investigative neuropathology. Brain Pathol 2002;12:67-86